China Pharma Holdings, Inc.
CPHI
$1.75
-$0.035-1.97%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.14M | 1.13M | 1.10M | 924.90K | 1.37M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.14M | 1.13M | 1.10M | 924.90K | 1.37M |
| Cost of Revenue | 1.27M | 1.29M | 1.62M | 1.94M | 1.66M |
| Gross Profit | -136.10K | -160.60K | -519.60K | -1.02M | -290.00K |
| SG&A Expenses | 593.00K | 1.03M | 478.00K | 211.80K | 594.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.89M | 2.33M | 2.19M | 2.32M | 2.29M |
| Operating Income | -758.60K | -1.20M | -1.09M | -1.39M | -916.10K |
| Income Before Tax | -785.60K | -1.22M | -1.12M | -1.44M | -955.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -785.60K | -1.22M | -1.12M | -1.44M | -955.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -785.60K | -1.22M | -1.12M | -1.44M | -955.90K |
| EBIT | -758.60K | -1.20M | -1.09M | -1.39M | -916.10K |
| EBITDA | -429.30K | -748.00K | -388.30K | -652.30K | -182.30K |
| EPS Basic | -0.24 | -0.53 | -0.65 | -0.89 | -0.72 |
| Normalized Basic EPS | -0.15 | -0.33 | -0.40 | -0.56 | -0.45 |
| EPS Diluted | -0.24 | -0.53 | -0.65 | -0.89 | -0.72 |
| Normalized Diluted EPS | -0.15 | -0.33 | -0.40 | -0.56 | -0.45 |
| Average Basic Shares Outstanding | 3.26M | 2.31M | 1.73M | 1.61M | 1.33M |
| Average Diluted Shares Outstanding | 3.26M | 2.31M | 1.73M | 1.61M | 1.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |